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The human immunodeficiency virus (HIV) p24 core protein is one of the most immunogenic of HIV
structural proteins. Infected individuals develop high titers of antibodies against p24 early in infection, which
makes anti-p24 antibodies important serological markers. However, despite the clinical importance of the
anti-p24 response, no systematic study to characterize the antigenic domains on the p24 protein has been
reported. We report here on the use of 12 overlapping fragments of the HIV type 1 p24 protein, synthesized
in bacteria as TrpE/Gag fusion proteins, to identify at least two and possibly three antigenic domains on the p24
protein. In addition, we note that different HIV-seropositive sera exhibited different patterns of reactivity with
the p24 domains presented on our fusion proteins.
The nucleocapsid of human immunodeficiency virus
(HIV) is composed of multiple subunits of a protein of
approximately 24,000 molecular weight called p24 (4, 20).
p24 is encoded by the HIV type 1 (HIV-1) gag gene along
with core proteins p17 and p15 as a polyprotein precursor (5,
16, 18, 21). Individuals infected with HIV mount a significant
humoral response against p24. Anti-p24 antibodies, along
with antibodies to the envelope proteins, are important for
diagnosis of exposure to HIV. Recent studies have docu-
mented a temporal decline in the prevalence of antibodies to
p24 which correlates with increasing severity of clinical
symptoms (3, 10, 15, 22). It has been suggested that a loss of
detectable p24 antibody, the appearance of circulating p24
antigen, and a decline in the number of CD4 cells are clinical
markers which foreshadow progression to clinical acquired
immune deficiency syndrome (6). Because of the importance
of antibodies to p24 in serological screening of blood samples
and as possible markers for disease progression, we wanted
to systematically characterize the antigenic domains of the
HIV-1 p24 protein. In this study we have generated twelve
TrpE/Gag fusion proteins presenting overlapping regions of
the p24 protein. Immunological analysis of HIV-seropositive
sera using these recombinant proteins has identified at least
two and possibly three antigenic domains on the p24 protein.
We constructed eight restriction enzyme deletion clones
of the HIV p24 gag gene by using the pATH (plasmid
amenable to making tryptophan hybrid) bacterial expression
plasmid (Fig. 1A and Table 1) (9, 13, 24). These plasmid
clones directed the synthesis of TrpE/Gag fusion proteins
which contained known regions of the p24 protein. Plasmid
constructions were confirmed by DNA sequencing of the 5'
vector-insert junction (2, 12) and were transformed into
Escherichia coli RR1 for recombinant protein synthesis.
Plasmid-containing bacteria were grown in pATH medium
and induced with 3-indoleacrylic acid as described else-
where (25). Insoluble recombinant proteins were isolated by
using a modification of the procedure described by Kleid et
al. (11). Bacteria were suspended in 20 ml of 50 mM Tris
hydrochloride (pH 7.5)-S5 mM EDTA-2 mg of lysozyme per
* Corresponding author.
ml and were left on ice for 1 h. The cells were disrupted by
the addition of Nonidet P-40 and NaCl to 0.75% and 0.35 M
final concentrations, respectively, and then sonicated. The
insoluble material was pelleted at 9,000 x g for 10 min and
stored at 4°C in 10 mM Tris hydrochloride (pH 7.5).
TrpE/Gag fusion proteins were analyzed on 0.1% sodium
dodecyl sulfate (SDS)-10% polyacrylamide gel electropho-
resis (PAGE) gels and stained with Coomassie blue (Fig.
2A). Because the TrpE protein itself does not purify well in
an insoluble form, total cell lysates of induced bacterial
cultures carrying the parental pATH plasmid were used as
controls on SDS-PAGE gels for staining (Fig. 2A and B,
lanes 2; Fig. 2C, lane 1) as well as for electroblotting (Fig. 3A
through C, lanes 1). In every case, the TrpE/Gag fusion
proteins were synthesized at significant levels, and the
amount of fusion protein relative to other bacterial proteins
could be increased by the lysis and centrifugation procedure.
The molecular mass of the fusion proteins relative to the
38-kilodalton (kDa) TrpE protein was generally what was
predicted on the basis of addition of a known number of HIV
residues. In addition, proteins from pATH 24-7, -8, -9, and
-10 (Fig. 1) migrate at sizes consistent with the presence of
extra residues added because of the continuation of the
reading frame after the last p24 nucleotide, as determined by
DNA sequencing. Therefore, the pATH 24-10 protein (Fig.
2B, lane 5) appears larger than the pATH 24-9 protein (Fig.
2B, lane 6), even though pATH 24-10 encodes fewer p24
amino acids.
To determine whether the HIV p24 determinants pre-
sented on our fusion proteins were reactive with serum
antibodies, we performed Western blot (immunoblot) analy-
sis as described elsewhere (25) by using the seven restriction
enzyme-generated TrpE/Gag fusion proteins. The results
(Fig. 3A and C) indicate that antibodies in an HIV-1-
seropositive reference serum react with amino-terminal p24
residues present in the pATH 24-1 and pATH 24-2 proteins
(Fig. 3A, lanes 2 and 3), but when the residues encoded
upstream and downstream of the PstI site (Fig. 1) are
presented separately (pATH 24-3 and pATH 24-4), then all
antibody reactivity is lost (Fig. 3A, lanes 4 and 5). Reactivity
can be recovered in pATH 24-5, which maintains the integ-
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FIG. 1. Schematic representation of HIV-1 proviral genome with
the gag DNA sequences expanded to indicate the p24 DNA segment
which was cloned into the pATH expression vector. The dark lines
represent HIV gaig DNA which was digested with the indicated
restriction enzymes prior to insertion into the pATH vector (A) or
pATH 24-1 DNA digested with Hiozdlll and subsequently digested
with exonuclease Ill (B). Clones generated by use of existing
restriction enzyme sites are designated pATH 24-1 through -7A15.
Clones derived from pATH 24-1 by exonuclease digestion are
designated pATH 24-8 through -11. The EcoRI site was regenerated
by ligation of the p24 PullI site with the blunt-ended EcoRI site of
the pATH vector. LTR. Long terminal repeat.
rity of the residues encoded by the PstI site (Fig. 3A, lane 6).
This indicates that an amino-terminal epitope exists on p24
and the upstream boundary of the epitope requires residues
encoded downstream of the XmtI site (nucleotide 821 [19]).
To better define the downstream boundary of the N-
terminal domain, bidirectional exonuclease III deletions
were performed (7) on pATH 24-1 DNA which had been
digested with HinzdIII. Four clones with increasing deletions
upstream from the HindIII site were isolated and were
designated pATH 24-8, -9, -10, and -11 (Fig. IB). The fusion
proteins from these clones were analyzed by SDS-PAGE
(Fig. 2B, lanes 4 through 7) and by Western blot, using our
HIV reference serum (Fig. 3B, lanes 3 through 6). Removal
of sequences between the HinidIII site (nucleotide 1260) and
nucleotide 1138 (pATH 24-10) did not abolish antibody
TABLE 1. HIV p24 nucleotide numbers in trpE-gag constructs"
Clone Restriction enzvme sites gag
pATH 24- att termini of inserted nucleotidep24 DNA no.
1 Pvl Il-BgIll 692-1644
2 Pv'ull-Hindlll 692-1260
3 PtuIIll-Pstl 692-963
4 Pstl-HindIIl 960-1260
5 XmtntI-Hi,tdlll 821-1260
6 Pstd-BgllIl 960-1644
7 Hinzdlll-Bglll 1256-1644
7A15 Hinidlll-Hpill 1256-1400
8 Pt-allI-X 692-1147
9 P1uIIl-X 692-1140
10 Pt-iiII-X 692-1138
11 Pt-all-X 692-836
Nucleotide numbers aire as given in reference 19. X. Endpoint generated
by exonuclease III digestion. The last p24 nucleotide in each exonLcIlease III
construct is listed in the thir-d column.
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FIG. 2. Coomassie-stained SDS-PAGE gels of TrpE/Gag fusion
proteins. Aliquots of fusion proteins recovered from insoluble
enrichment preparations were electrophoresed on 0.1% SDS-10%
PAGE gels along with whole-bacterial-cell lysate from cells synthe-
sizing the TrpE protein without HIV amino acids (panels A and B,
lanes 2: panel C. lane 1). The TrpE protein is indicated by the arrow.
Molecular markers (Bio-Rad Laboratories) are shown in lane 1 of
each panel. with the mass in kilodaltons of each standard given at
the left. (A) Lane 3. pATH 24-1; lane 4. pATH 24-2; lane 5, pATH
24-3: lane 6. pATH 24-4: lane 7. pATH 24-5. (B) Lane 3, pATH 24-2;
lane 4. pATH 24-8: lane 5. pATH 24-10; lane 6. pATH 24-9; lane 7.
pATH 24-11. (C) Lane 2, pATH 24-6: lane 3. pATH 24-7; lane 4,
pATH 24-7A15.
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FIG. 3. Western immunoblot analysis of TrpE/Gag fusion pro-
teins with an HIV-seropositive reference serum. Aliquots of insol-
uble enrichment preparations of TrpE/Gag fusion proteins identical
to those used for Fig. 2 were electrophoresed on 0.1% SDS-10%
PAGE gels, transferred to nitrocellulose, and used for Western
immunoblot analysis. All panels contained whole bacterial lysate
containing TrpE protein without any HIV amino acids in lane 1. (A)
Lane 2, pATH 24-1; lane 3, pATH 24-2; lane 4, pATH 24-3; lane 5,
pATH 24-4; lane 6, pATH 24-5. (B) Lane 2, pATH 24-2; lane 3.
pATH 24-8; lane 4, pATH 24-10; lane 5, pATH 24-9; lane 6, pATH
24-11. (C) Lane 2, pATH 24-6; lane 3, pATH 24-7; lane 4, pATH
24-7A15. Molecular mass in kilodaltons is given at the left for
markers (Bio-Rad), which were electroblotted onto the nitrocellu-
lose filter and then Coomassie stained and destained.
reactivity (Fig. 3B, lane 4). However, removal of sequences
up to nucleotide 836 (pATH 24-11) completely abolished
antibody reactivity (Fig. 3B, lane 6). This analysis indicates
that the amino-terminal antigenic domain is composed of, at
most, 105 amino acids encoded between gaig nucleotides 821
and 1138.
The C-terminal region of p24 also appears to contain major
antibody-reactive domains. Both pATH 24-6 and -7 fusion
proteins were reactive with serum antibodies in our refer-
ence serum (Fig. 3C, lanes 2 through 4). It is not likely that
this reactivity is directed toward the amino-terminal domain,
because the p24 residues in pATH 24-6 are encoded begin-
ning at the PstI site and also because the residues encoded
between the PstI and HindIII sites (pATH 24-4) were not
reactive when presented by themselves. Thus, it is possible
that an epitope which requires amino acids encoded by an
intact HindIII site is present or that the epitope(s) is com-
pletely contained on the region presented on the pATH 24-7
fusion protein. The reference serum used in the Western blot
analysis as well as all those used in the immunodot blot
analysis was characterized as lacking antibodies to p15 by
Western blot when Dupont human T-cell lymphotropic virus
type III-inactivated antigen strips were used (data not
shown). Therefore it is likely that the reactivity observed in
Fig. 3C (lanes 2 and 3) is directed toward at least one
C-terminal antigenic domain on the p24 protein downstream
of the HindlIl site (Fig. 1A). To confirm this, clone pATH
25-7A15 was constructed (Fig. 1A and Table 1). Western
blot analysis of this protein (Fig. 3C, lane 4) with our
reference serum detected strong reactivity, indicating the
presence of an extreme C-terminal domain in p24.
We next wanted to determine whether the putative p24
domains detected by our reference serum are also detected
by serum antibodies from other HIV-infected individuals.
We therefore screened our TrpE/Gag fusion proteins by
using 14 additional sera previously characterized as contain-
ing antibodies to the HIV-1 gp4l envelope protein by our
immunodot blot assay (25) and, in the case of pATH 24-
7A15, by Western blot. One of the advantages of the
immunodot blot is that many different antigens may be tested
for antibody reactivity simultaneously with only minimal
amounts of patient sera. As a negative control for antibodies
against the TrpE or other bacterial proteins, the pATH 24-11
protein was included on each antigen strip. This protein does
not contain the p24 epitopes described here and appears
negative on Western blot (Fig. 3B, lane 6). The patterns of
reactivity to our TrpE/Gag fusion proteins can be divided
into four groups based on the immunodot blot results: (i)
those that do not have detectable anti-p24 antibodies, (ii)
those that have antibodies which recognize the C terminus
only, (iii) those which recognize the N terminus only, and
(iv) those which recognize both N and C termini. The first
group contained three sera which did not contain detectable
anti-p24 antibodies. Two of these sera were confirmed p24
antigen positive by Abbott human T-cell lymphotropic virus
type III antigen enzyme immunoassay. Therefore, these two
sera which were anti-envelope positive, anti-p24 negative,
and p24 antigen positive were similar to serum samples from
individuals exhibiting clinical symptoms of acquired immune
deficiency syndrome (1, 17). A second group of four p24
antigen-negative sera contained antibodies reactive only
with the C-terminal domain(s) present on pATH 24-1, -6, and
-7. A third group was defined by a single serum which
recognized only the amino-terminal (PsstI) domain. A fourth
group of six p24 antigen-negative sera contained antibodies
reactive with both the amino-terminal domain (pATH 24-1,
-2, and -5) and the C-terminal domain(s) (pATH 24-1, -6, and
-7). Three sera from individuals not infected with HIV were
tested by immunodot blot and did not contain detectable
antibodies to any TrpE/Gag fusion proteins. No E. coli-
specific antibodies were detected on the control dots, which
indicates that the reactivity observed was directed against
the HIV domains present on the fusion proteins and not
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against the TrpE protein itself or the contaminating bacterial
proteins.
Of the 10 sera that recognized the C-terminal domain(s)
presented by pATH 27-6 and -7, 7 have higher titers of
antibodies specific for the pATH 24-6 protein than of anti-
bodies for the pATH 24-7 protein, as judged from the
intensity of the dot blot results with equivalent amounts of
immobilized antigen. This implies that these seven sera
contain antibodies reactive against a domain which is com-
posed of residues encoded by sequences which flank the
Hindlll site as well as antibodies to an extreme C-terminal
domain formed by residues encoded downstream of the
HindlIl site. Western blot analysis of these seven sera with
pATH 24-7A15 confirmed that all of these sera also contain
antibodies to the extreme C-terminal region of p24. Overall,
11 of the 12 sera which contain anti-p24 antibodies (including
our reference serum [Fig. 3]) were reactive with the pATH
24-7A15 protein, which implies that this region may encode
an immunodominant domain. Only one serum was found to
be reactive with the N-terminal p24 domain exclusively.
It has been reported previously that sera characterized by
Western blot as lacking antibodies to p15 were reactive with
p24 domains present on a protein analogous to our pATH
24-6 protein (14). Our results are consistent with this finding
and show that an immunodominant domain exists at the
extreme C terminus of p24 as presented on the pATH
24-7A15 protein. In addition, a second C-terminal domain,
detected by a majority of the sera tested, requires amino
acids encoded by the HiidIlll site. A plot of the hydropho-
bicity of the p24 protein (not shown) is consistent with these
results, as it predicts that the regions encoded around the
PstI and HindlIl sites and the C terminus of p24 are strongly
hydrophilic and thus may be located on the external surface
of the native p24 protein.
Although others have expressed the HIV-1 gag gene in E.
coli (8, 23), our panel of TrpE/Gag fusion proteins is de-
signed to present discrete portions of the intact protein so
that the pattern of the antibody response to p24 domains in
a given serum sample can be characterized. Judged by the
sequence of HIV (19, 21), the gaig gene products are not
glycosylated in vivo. Therefore our recombinant proteins
synthesized in bacteria should be similar to the native
protein. Indeed, the reactivity of our proteins with patient
sera indicates that epitopes similar to those on the native p24
protein are presented by our TrpE/Gag fusion proteins.
However, it is not clear to what extent the recombinant
peptides are folded back into the native conformation. Our
analysis using Western blot and immunodot blot does not
necessarily detect conformational epitopes. It is therefore
likely that the domains we describe here are linear epitopes
of the p24 protein backbone and that other antigenic domains
formed by conformational folding of the native protein do
exist but may not be detected by our analysis.
Our ability to distinguish different patterns of reactivity to
p24 domains indicates that it is possible for individuals to
react differently to the domains on the p24 protein. The
C-terminal domains appear to be immunodominant; i.e.. in
all individuals with detectable anti-p24 antibodies, the anti-
bodies recognized this region. In contrast, the amino-ter-
minal domain may or may not be recognized. The nature of
the antibody response to p24 may be influenced by the
nature of the strain of HIV that an individual is infected with
as well as the clinical state of the individual. Serological
studies using clinically well characterized serum panels will
be helpful in further clarifying the response to p24.
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